---

$0.58

-0.1640 ( -22.20% ) 3.6M

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-04-04	Sale	-372.00	Awad Antoine
2024-04-04	Sale	-188.00	Dooley Mary Beth
2024-03-21	Sale	-4000.00	Flynn James P
2024-01-04	Sale	-24923.00	Barrett Peter
2024-01-04	Sale	-14678.00	Hurter Patricia N.
2023-11-14	Sale	-3666.00	Awad Antoine
2023-11-14	Sale	-15332.00	JENSEN MICHAEL VANGSTED
2023-11-14	Sale	-5591.00	Brennan Aoife